지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 54 - 64 (11page)
이용수
초록· 키워드
오류제보하기
Background: Panax ginseng Meyer (P. ginseng) is a traditional natural/herbal medicine. The amelioration on inflammatory bowel disease (IBD) activity rely mainly on its main active ingredients that are referred to as ginsenosides. However, the current literature on gut microbiota, gut microbiota-host co-metabolites, and systems pharmacology has no studies investigating the effects of ginsenoside on IBD.
Methods: The present study was aimed to investigate the role of ginsenosides and the possible underlying mechanisms in the treatment of IBD in an acetic acid-induced rat model by integrating metagenomics, metabolomics, and complex biological networks analysis. In the study ten ginsenosides in the ginsenoside fraction (GS) were identified using Q-Orbitrap LC-MS.
Results: The results demonstrated the improvement effect of GS on IBD and the regulation effect of ginsenosides on gut microbiota and its co-metabolites. It was revealed that 7 endogenous metabolites, including acetic acid, butyric acid, citric acid, tryptophan, histidine, alanine, and glutathione, could be utilized as significant biomarkers of GS in the treatment of IBD. Furthermore, the biological network studies revealed EGFR, STAT3, and AKT1, which belong mainly to the glycolysis and pentose phosphate pathways, as the potential targets for GS for intervening in IBD.
Conclusion: These findings indicated that the combination of genomics, metabolomics, and biological network analysis could assist in elucidating the possible mechanism underlying the role of ginsenosides in alleviating inflammatory bowel disease and thereby reveal the pathological process of ginsenosides in IBD treatment through the regulation of the disordered hosteflora co-metabolism pathway.
Methods: The present study was aimed to investigate the role of ginsenosides and the possible underlying mechanisms in the treatment of IBD in an acetic acid-induced rat model by integrating metagenomics, metabolomics, and complex biological networks analysis. In the study ten ginsenosides in the ginsenoside fraction (GS) were identified using Q-Orbitrap LC-MS.
Results: The results demonstrated the improvement effect of GS on IBD and the regulation effect of ginsenosides on gut microbiota and its co-metabolites. It was revealed that 7 endogenous metabolites, including acetic acid, butyric acid, citric acid, tryptophan, histidine, alanine, and glutathione, could be utilized as significant biomarkers of GS in the treatment of IBD. Furthermore, the biological network studies revealed EGFR, STAT3, and AKT1, which belong mainly to the glycolysis and pentose phosphate pathways, as the potential targets for GS for intervening in IBD.
Conclusion: These findings indicated that the combination of genomics, metabolomics, and biological network analysis could assist in elucidating the possible mechanism underlying the role of ginsenosides in alleviating inflammatory bowel disease and thereby reveal the pathological process of ginsenosides in IBD treatment through the regulation of the disordered hosteflora co-metabolism pathway.
목차
ABSTRACT
1. Introduction
2. Materials and methods
3. Results
4. Discussion
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
Intestinal research
2024 .01
-
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
Gut and Liver
2019 .01
-
Gut microbiota-mediated pharmacokinetics of ginseng saponins
Journal of Ginseng Research
2018 .06
-
Microbial Modulation in Inflammatory Bowel Diseases
Immune Network
2022 .12
-
Immunological pathogenesis of inflammatory bowel disease
Intestinal research
2018 .01
-
Association of Inflammatory Bowel Disease (IBD) with Depressive Symptoms in the United States Population and Independent Predictors of Depressive Symptoms in an IBD Population: A NHANES Study
Gut and Liver
2017 .07
-
Host-microbial Cross-talk in Inflammatory Bowel Disease
Immune Network
2017 .02
-
우리나라 염증장질환의 현황
대한의사협회지
2021 .09
-
Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care
Intestinal research
2022 .10
-
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Intestinal research
2022 .04
-
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Intestinal research
2023 .04
-
장내 미생물과 염증장질환
대한의사협회지
2021 .09
-
인삼의 열처리 과정 중 생성되는 3종의 수산화진세노사이드에 대한 연구
생약학회지(Korean Journal of Pharmacognosy)
2020 .12
-
Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Effects of gut microbiota on the pharmacokinetics of protopanaxadiol ginsenosides Rd, Rg3, F2, and compound K in healthy volunteers treated orally with red ginseng
Journal of Ginseng Research
2020 .07
-
Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models
Intestinal research
2020 .01
-
염증장질환의 역학 및 진단
대한의사협회지
2021 .09
-
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Immune Network
2017 .02
-
Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?
Intestinal research
2021 .01
-
Surgical Strategies of Pediatric IBD through Adult IBD (I): UC
대한외과학회 학술대회 초록집
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2023-524-000401522